Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 1/20 | 0.50 |
| ▸ | GLI1 | P08151 | 2/20 | 0.46 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 6/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7122076 | 1.00 | SCN4A (0.50) | SCN4AGLI1NOS2NOS3NOS1 | |
| SCHEMBL3332522 | 0.96 | SCN4A (0.50) | SCN4AGLI1NOS2NOS3NOS1 | |
| SCHEMBL6861704 | 0.93 | SCN4A (0.48) | SCN4AGLI1NOS2NOS3NOS1 | |
| SCHEMBL13902906 | 0.91 | SCN4A (0.47) | SCN4AGLI1NOS2NOS3NOS1 | |
| SCHEMBL31717193 | 0.85 | SCN4A (0.43) | SCN4AGLI1NOS2NOS3NOS1 | |
| SCHEMBL31717480 | 0.85 | SCN4A (0.43) | SCN4AGLI1NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL31717753 | 0.84 | SCN4A (0.42) | SCN4AGLI1NOS2NOS3NOS1 | |
| SCHEMBL894617 | 0.82 | GLI1 (0.66) | SCN4AGLI1NOS2NOS3NOS1 | |
| SCHEMBL255493 | 0.82 | GLI1 (0.66) | SCN4AGLI1NOS2NOS3NOS1 | |
| SCHEMBL490079 | 0.82 | GLI1 (0.66) | SCN4AGLI1NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2002096361-A2 | 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | SCN4A 4308/4885GLI1 1250/4885NOS2 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.